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Background: The expansion of newborn screening pro-
grams has increased the number of newborns diag-
nosed with inborn errors of metabolism in the pre-
symptomatic phase, but it has also increased the number
of costly, stress-producing false-positive results. Be-
cause propionylcarnitine (C3) is one of the analytes
most frequently responsible for false-positive results,
we aimed to develop a rapid liquid chromatography–
tandem mass spectrometry (LC-MS/MS) method to
identify free methylmalonic (MMA) and 3-OH propi-
onic (3OH-PA) acids in blood spots.
Methods:We studied newborn screening spots from 250
healthy controls; 124 from infants with abnormal C3, of
whom only 5 (4%) were truly affected; 124 from infants
with altered isolated methylmalonylcarnitine; and 4
from clinically diagnosed patients. Whole blood was
eluted from a 3.2-mm dried blood spot by a CH3CN/H2O
7:3 and 5 mL/L formic. This extract was injected into a
LC-MS/MS equipped with pneumatically assisted elec-
trospray without derivatization. Total analysis time was
5 min per sample.
Results: The assays were linear up to 3300 nmol/L for
both metabolites. Intra- and interassay imprecision data
were 3.6%–8% and 3.1%–6%, respectively, for MMA
and 5.2%–20% and 3.6%–17% for 3OH-PA. Limit of
detection and limit of quantitation were 1.95 and
4.2 mol/L, respectively, for MMA and 8 and 10 mol/L
for 3OH-PA. The recoveries were 92.9%–106.1%. No
deterioration was noted on the columns after 500 chro-
matographic runs. If the new method had been used as
a 2nd-tier test for the 124 samples, only the 5 true
positives would have been recalled for additional sam-
ples, and the positive predictive value would have been
100%.
Conclusions: This method has the potential to mark-
edly reduce false-positive results and the associated
costs and anxiety. It may also be suitable for diagnosing
and routinely monitoring blood spots for methylma-
lonic aciduria and propionic acidemia.
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The introduction of an expanded liquid chromatography–
tandem mass spectrometry (LC-MS/MS)3–based new-
born screening program has significantly increased early
diagnoses of inborn errors of metabolism. False-positive
screening results have also increased since the time when
neonatal screening was limited to phenylketonuria and
congenital hypothyroidism (1, 2). This increase in retest-
ing has had important consequences, including increased
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laboratory analyses, personnel costs for repeat tests, and
considerable anxiety for parents (3–6). The impact of a
screening recall on a family is substantial (7, 8). Even after
a normal retesting, a screening recall often results in
increased anxiety over a child’s health, an altered parent-
child relationship, and increased hospitalizations for un-
related illnesses (2, 6, 9). Many authors have tried to
assess what levels of parental stress are acceptable (10 ).
An expanded program for newborn screening by
LC-MS/MS was established in Tuscany in 2001 (the first
regional expanded newborn screening program in Italy).
Our experience shows that some metabolites—propionyl-
carnitine (C3), isobutyryl/butyrylcarnitine (C4), and ty-
rosine—are more likely than others to cause false-positive
results and increase recall rates. C3, in particular, causes a
high number of false-positive results. In 67 000 new-
borns screened by our center between November 2004
and November 2006, the recall rate for altered C3 was20
percent of all recalls. Diagnosis of propionic acidemia
(PA) was confirmed in 2 patients and methylmalonic
aciduria in 3 patients. The positive predictive value of C3
was 4%.
These data encouraged us to develop a strategy to
reduce false-positive rates and improve the positive pre-
dictive value of an initial abnormal result.
Materials and Methods
Chemical standard 2-hydroxypropionic acid [lactic acid
(LA)], methylmalonic acid (MMA), and succinic acid (SA)
were purchased from Sigma-Aldrich; 3-OH-propionic
acid (3OH-PA) was from Tokyo Chemical Industries. A
working calibrating solution containing 10 mol/L of
each was prepared in CH3CN/H2O 7:3 containing 5 mL
formic acid per liter. MMA (methyl-D3) was from Cam-
bridge Isotopes Laboratories.
We tested 250 newborn screening spots from healthy
controls, 119 spots with false-positive results due to
abnormal values of C3, and 124 spots with isolated
methylmalonylcarnitine (C4DC) outside the reference in-
terval (Table 1), although we have not presupposed any
recall for altered isolated C4DC. In addition, we studied
newborn screening spots from 9 patients with confirmed
diagnoses: 4 patients with PA and 5 patients with meth-
ylmalonic aciduria. Two patients with PA (PA3 and PA4)
and 3 with methylmalonic aciduria (MMA1, MMA2, and
MMA3) were identified by newborn screening; in 2 PA
patients (PA1 and PA2) and 2 methylmalonic aciduria
patients (MMA4 and MMA5), diagnosis was made clini-
cally before the expanded newborn screening program
was started. In the latter cases, stored dried blood spots
from newborn screening were retrospectively analyzed.
PA1 and PA2 had acute neonatal onset, whereas PA3 and
PA4 were asymptomatic when newborn screening results
were available. MMA1 was due to maternal cobalamin
deficiency; in MMA2 no mutation was identified in the
MUT4 (methylmalonyl coenzyme A mutase) gene, and
complementation studies are in progress. MMA3, MMA4,
and MMA5 had mutase deficiencies; MMA2 and MMA3
had clinical symptoms when recalled for neonatal screen-
ing; MMA4 had acute neonatal onset; and MMA5 had
acute late onset.
Specimens of dried blood spots used as controls were
collected from neonates born in Tuscany. Our local ethics
committee approved the procedure. Blood collection for
newborn screening purposes is made between 48 and 72 h
of life. Blood taken by heel stick is spotted on filter paper
(903, Whatman), dried, and sent by courier to the screen-
ing center. Blood spot samples are stored at room tem-
perature until analysis.
We punched a 3.2-mm filter paper disk containing
3.4 L whole blood from each dried blood spot and
4 Human gene: MUT, methylmalonyl coenzyme A mutase.
Table 1. MMA, 3OH-PA, C3, and C4DC in samples from screening patients, false-positives samples, C4DC-positive spots,
and controls.
Sample Diagnosis year MMA, mol/L 3OH-PA, mol/L C3, mol/L C4DC, mol/L
PA1 2002 NDa 76 7.89 0.03
PA2 2002 ND 69.4 8.79 0.03
PA3 2006 ND 104 10.76 0.14
PA4 2005 ND 106.7 11.83 0.41
MMA1 2006 37.4 11.3 7.25 0.25
MMA2 2006 109.2 31.9 9.84 0.32
MMA3 2005 111.1 29.9 6.88 0.54
MMA4 1999b 83.5 29.4 0.86b 0.09b
MMA5 2002b 190 27.9 4.4b 0.18b
False-positive samples (n  124) ND ND 6.01–15.2 WR
C4DC-positive samples (n  124) ND ND WRa 0.55–1.1
Controls (n  250) ND ND WR WR
Normal values ND ND 0.2–5.65 0.04–0.54
a ND, Not detectable; WR, within accepted interval.
b Newborn screening spot retrospectively tested in 2005.
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extracted it for 15 min with 200 L of a solution con-
taining CH3CN/H2O 7:3 and 5 mL/L formic acid, plus
330 nmol/L labeled MMA as internal standard. Calibra-
tors, containing internal standard at 330 nmol/L, were at
concentrations of 0, 33, 165, 330, and 3300 nmol/L. We
injected 2 L into the LC column. For enriching studies,
we evaluated linearity by analyzing supplemented
3.2-mm dried blood spots prepared at 0, 33, 165, 330, and
3300 nmol/L. The resulting calibration values were 0,
1.947, 9.735, 19.47, and 194.7 mol/L, respectively, com-
pared with blood (3.4 L diluted 59-fold). The solution
was shaken on a vortex-mix system for 15 min at room
temperature, and 2 L solution was injected into the mass
spectrometer.
The hardware configuration includes an Applied Bio-
systems/MDS Sciex API 4000™ Triple-Quad Mass Spec-
trometer equipped with the TurboV-Spray® source with
the turbo gas temperature set at 425 °C. The source
Fig. 1. Extract ion chromatograms of control (A), C3 false positive (B), PA (C), and methylmalonic aciduria (D).
Table 2. MRM transitions, DP, CE, quantification strategies, and retention times.a
MRM transitions
Measured
compound
Chromatographic
retention time, min Polarity
Precursor
ion
Fragment
ion DP, V CE, eV Quantification strategy
Lactic acid 1.08  89 59 50 14
3OH-PA 1.24  89 59 50 14 External calibration
SA 1.30  117.1 73 40 12
2H3-MMA 2.37  120.1 76 40 12
2.39  117.1 73 40 12 Isotopic dilution
a DP, Declustering potential; CE, collision energy.
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operates in negative ionization polarity at a potential of
4500 V. We performed multiple reaction monitoring
(MRM) measurements using declustering potential and
collision energy values as automatically optimized by the
software functionality for each of the analytes. A list of
exploited transitions, collision energies, and declustering
potentials is reported in Table 2. The choice of ionization
conditions for each analyte was made to give maximum
sensitivity in the experimental conditions.
We used an Agilent 1100 Quaternary Capillary-Pump
for chromatography and a Gemini C6-phenyl, 3-m 100
2-mm (i.d.) column and a 4  2-mm precolumn cartridge
(Phenomenex) for separation. The chromatographic run
was performed at 200 L/min with an isocratic profile of
40:60 between mobile phase of H2O (eluent A) and
CH3CN (eluent B), each containing 5 mL/L formic acid.
The next injection was performed after 5 min. Retention
times are reported in Table 2.
Results
After extensive evaluation of several LC columns working
either in normal phase or in reversed phase (data not
shown), the best performance resulted from the C6-
phenyl column: the eluent is identical to that used during
newborn screening for acylcarnitines and amino acids. No
substantial modifications were noted when 100% metha-
nol was used both as extraction solvent and eluent B
during a chromatographic run. In these conditions, the
isobaric SA and MMA were completely resolved. The
respective retention times were 1.30 and 2.39 min. In
the case of LA and 3OH-PA, the retention times were 1.08
and 1.24 min, respectively (Fig. 1).
All analytes are acids and display poor sensitivity
when ionized in positive mode. This implies that their
measurement should be done in negative ion mode for
better sensitivity. As already mentioned, where the isoto-
pically labeled form of MMA was available, measure-
ments were made by isotopic dilution strategy. The re-
lated labeled standard of 3OH-PA was not available, so
we used the labeled MMA, which has chemical similari-
ties, as internal standard.
The assays were linear up to 3300 nmol/L for both
metabolites, but for the routine purpose of the protocol
(screening), the MMA and 3OH-PA concentrations in
samples from unaffected neonates were below detection
limits. Intra- and interday imprecision data are reported
in Table 3. For blood spots with added analyte, the limit of
detection or limit of the blank (mean plus 3 SD of blank)
for MMA was 1.95 mol/L and the limit of quantification
(mean plus 10 SD of blank) 4.2 mol/L; for 3OH-PA the
limit of detection was 8 mol/L and the limit of quanti-
tation 10 mol/L. Intra- and interday imprecision (CV)
was in the range of 3.5%–7.8% and 3.1%–6%, respectively,
for MMA and 5.2%–19.6% and 3.6%–16.9% for 3OH-PA.
Imprecision could not be determined for blood spots that
had not been supplemented because the concentrations of
MMA and 3OH-PA were lower than the limit of quanti-
tation. The recoveries ranged from 92.9% to 106.1%. No
deterioration was noted on the columns after 500 chro-
matographic runs.
Table 3. Intra- and interday imprecision.
Metabolite
Amount added,
nmol/L
Intraday CV
(n  6), %
Interday CV
(n  6), %
Mean result,
mol/L
Recovery
(n  6)
Blood 1
MMA 0 0 0.0 0.0
MMA 33 3.5 3.1 34.0 103.1
MMA 165 4.9 3.7 158.0 95.8
MMA 330 7.8 6.0 336.2 101.9
MMA 3300 3.8 4.8 3299.7 100.0
PA 0 0 0.0 0.0
PA 33 19.6 16.9 32.8 92.9
PA 165 6.6 4.8 169.6 100.3
PA 330 5.2 3.6 325.4 100.6
PA 3300 5.6 6.7 3300.2 100.3
Blood 2
MMA 0 0 0.0 0.0
MMA 33 7.8 6.1 42.6 123.0
MMA 165 9.4 8.0 175.0 106.1
MMA 330 1.4 1.8 308.9 93.6
MMA 3300 1.5 2.7 3301.5 100.0
PA 0 0 0.0 0.0
PA 33 9.3 17.1 30.7 93.2
PA 165 4.4 10.6 168.3 102.0
PA 330 7.2 10.5 328.9 96.7
PA 3300 2.5 3.3 3300.0 100.0
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Between November 2004 and November 2006 (n 
67 586), the Newborn Screening Tuscany program, lim-
ited to LC-MS/MS testing, had a detection rate of 1:1950
and a false-positive rate of 0.83%. Of 564 total recalls, 124
(22%) were for abnormal values of isolated C3 (normal
values 0.2 to 5.65 mol/L) and 1 or more abnormal ratios
(C3/free carnitine 0.03–0.13; C3/C4 1.1–12.5; C3/C16
0.11–1.16). Only 5 of the 124 were true positives: 3
methylmalonic acidurias and 2 PAs.
To assess whether 2nd-tier testing could be effective,
we applied it to 250 blood spots reported as normal
during newborn screening by LC-MS/MS, 124 spots re-
called for abnormal values of C3, and 124 spots having
C4DC outside the accepted intervals. In addition, we
tested 9 truly positive newborn screening blood spots (5
methylmalonic acidurias and 4 PAs). No signal corre-
sponding to free diagnostic acids was detected for con-
trols, false positives, or C4DC-positive spots. Free 3OH-
PA, free MMA, C3, and C4DC carnitine values from
affected newborns are reported in Table 1.
This methodology succeeds in distinguishing true pos-
itives from false positives and controls, as shown in Fig. 1.
In each panel, the extracted ion chromatograms referring
to the implicated metabolites are highlighted for both the
control/false positive and the affected patient.
Discussion
LC-MS/MS is increasingly gaining acceptance in clinical
laboratories. In addition to its benefits in terms of sensi-
tivity and specificity, it enables multiple compounds to be
analyzed at one time. Routine analysis of multiple com-
ponents in one fast step has been implemented in clinical
laboratories for neonatal screening, steroid profiling, and
so on. The method we describe allows qualification of the
disorder and reduces the false-positive rate due to abnor-
mal values of C3 and/or C4DC carnitines during new-
born screening. To our knowledge, this is the first time
free MMA and 3OH-PA involved in propionic and meth-
ylmalonic acidurias have been both monitored and quan-
tified using a single blood spot sample.
Other methods that measure MMA and separate it
from SA as n-butyl ester derivatives in plasma and urine
by LC-MS/MS have been published by several authors
(11–13). There are several advantages of our method. It
reveals contemporaneously free 3OH-PA and MMA,
clearly separated from each other and differentiated from
LA and SA by a fast chromatographic run in the same
spot used in newborn screening. In addition, sample
preparation is minimal and quick, without a derivatiza-
tion step. Moreover, our method permits follow-up stud-
ies and a 1st rapid evaluation in suspected patients.
MS is a promising tool in clinical analysis, both for
research (mainly through proteomic and metabolomic
approaches) and in routine procedures (through the
quantization of targeted metabolites and markers). In the
past, mass spectrometry performance was noted for sen-
sitivity, resolution, and selectivity factors. Today, the
clinical laboratory demands those factors and also short-
and long-term robustness. An analytical methodology
cannot be exploited in the clinical domain if it is lacking
robustness and requires labor-consuming sample prepa-
ration (14, 15).
Our methodology is capable of monitoring and quan-
tifying MMA and 3OH-PA during newborn screening as
a 2nd-tier test. It can follow up on and diagnose PA and
methylmalonic acidurias. The method is precise and ro-
bust and therefore suitable for implementation in routine
clinical screening programs and quantification environ-
ments. In our opinion, the application of this method in
newborn screening analysis will reduce or even eliminate
false-positive results for C3 and prevent a great deal of
unnecessary anxiety for parents and associated problems
(2 ). New and better strategies should be developed to
provide testing options that, applied to newborn screen-
ing programs, reduce recall rate, overall expenses, and
parental anxiety.
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